These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32948461)

  • 21. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
    Melaragni F; Levy C; Pedrazzi J; Andersen M
    J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacists' perceptions regarding feasibility, acceptability, and usefulness of student-delivered naloxone education services in community pharmacy: A mixed methods study in Alabama.
    Hohmann L; Maxson R; McDowell L
    J Am Pharm Assoc (2003); 2023; 63(6):1731-1742.e4. PubMed ID: 37619850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
    Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
    Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
    Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
    Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naloxone availability in independent community pharmacies in Georgia, 2019.
    Gilbert L; Elliott J; Beasley L; Oranu E; Roth K; Nguyễn J
    Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):63. PubMed ID: 34419089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study.
    Burstein D; Baird J; Bratberg J; Donovan E; Soipe A; Tapper A; Case P; Walley AY; Green TC
    J Am Pharm Assoc (2003); 2020; 60(2):304-310. PubMed ID: 31870862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
    Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
    J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of academic detailing for pharmacists on opioid use disorder and harm reduction.
    DiPaula BA; Cooke CE; Boyle CJ; Love RC
    J Am Pharm Assoc (2003); 2022; 62(1):241-246. PubMed ID: 34690080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
    Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
    BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.
    Lai RK; Friedson KE; Reveles KR; Bhakta K; Gonzales G; Hill LG; Evoy KE
    J Am Pharm Assoc (2003); 2022; 62(6):1725-1740. PubMed ID: 35989151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of pharmacist counseling to enhance the accessibility of naloxone nasal spray to patients in a community pharmacy setting.
    Napoli K; Grant M; Remines J; Nadpara P; Goode JR
    J Am Pharm Assoc (2003); 2021; 61(4S):S127-S134. PubMed ID: 33441280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies.
    Xu J; Mukherjee S
    Drug Alcohol Depend; 2021 Oct; 227():109012. PubMed ID: 34482035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.
    Roberts AW; Carpenter DM; Smith A; Look KA
    Res Social Adm Pharm; 2019 Feb; 15(2):222-225. PubMed ID: 29650444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Public Health and Pharmacy Partnerships in Opioid Harm Reduction: Responding to Community Needs.
    Medina S; Tomaszewski R; Chhen S; Hanson A; Mueller A; Palombi LC
    Prog Community Health Partnersh; 2021; 15(1):37-46. PubMed ID: 33775959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Piloting an opioid callback program in community pharmacies.
    Hernandez SE; Gilson AM; Gassman M; Ford JH
    J Am Pharm Assoc (2003); 2023; 63(6):1796-1802. PubMed ID: 37574197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is known about community pharmacy supply of naloxone? A scoping review.
    Nielsen S; Van Hout MC
    Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
    Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
    J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies.
    Spivey CA; Wilder A; Chisholm-Burns MA; Stallworth S; Wheeler J
    J Am Pharm Assoc (2003); 2020; 60(5):694-701.e1. PubMed ID: 32146134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.